Search
Feed aggregator
Tris Pharma Gets FDA Approval for Non-Stimulant ADHD Medication
Tris Pharma Gets FDA Approval for Non-Stimulant ADHD Medication 5/30/2024
Biohaven’s Phase I Data for Lead Protein Degrader Disappoints Investors
Biohaven’s Phase I Data for Lead Protein Degrader Disappoints Investors 5/30/2024
BioSpace x DIA: Advanced Therapy Product Regulatory Confusion
BioSpace x DIA: Advanced Therapy Product Regulatory Confusion 5/30/2024
BioNTech Secures $145M to Boost mRNA Vaccine Capabilities in Africa
BioNTech Secures $145M to Boost mRNA Vaccine Capabilities in Africa 5/30/2024
Early-Stage Biotechs Now Tying CEO Pay Packages to Capital Raises
Early-Stage Biotechs Now Tying CEO Pay Packages to Capital Raises 5/30/2024
Moving Up: 5 Tips for Transitioning From Co-Worker to Manager
Moving Up: 5 Tips for Transitioning From Co-Worker to Manager 5/30/2024
Intermittent fasting shows promise in improving gut health, weight management
A new study by researchers from Arizona State University and their colleagues highlights a dietary strategy for significant health improvement and weight management.
Participants following an intermittent fasting and protein-pacing regimen, which involves evenly spaced protein intake throughout the day, saw better gut health, weight loss and metabolic responses. These benefits were notably greater than those seen with simple calorie restriction.
Merck’s Potential $3B EyeBio Acquisition Puts Drugmaker Back in Ophthalmology
Merck’s Potential $3B EyeBio Acquisition Puts Drugmaker Back in Ophthalmology 5/29/2024
Amgen Wins FDA Approval for First Biosimilar to AstraZeneca’s Soliris
Amgen Wins FDA Approval for First Biosimilar to AstraZeneca’s Soliris 5/29/2024
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters 5/29/2024
Insmed Stock Surges After Brensocatib Aces Phase III Lung Disease Study
Insmed Stock Surges After Brensocatib Aces Phase III Lung Disease Study 5/29/2024
AstraZeneca’s Ambitious Target, Pharma Layoffs Continue and ASCO
AstraZeneca’s Ambitious Target, Pharma Layoffs Continue and ASCO 5/29/2024
Who Will the Next “Big Pharma” Players Be?
Who Will the Next “Big Pharma” Players Be? 5/29/2024
How Realistic is AstraZeneca’s $80B Revenue Target by 2030?
How Realistic is AstraZeneca’s $80B Revenue Target by 2030? 5/29/2024
J&J Scores Phase III Victory in Major Depressive Disorder
J&J Scores Phase III Victory in Major Depressive Disorder 5/29/2024
Biopharma IPOs From the First Half of 2024
Biopharma IPOs From the First Half of 2024 5/29/2024
Can AI Help Biopharma Companies Go Green?
Can AI Help Biopharma Companies Go Green? 5/29/2024
AstraZeneca Touts Early-Stage Results for Oral PCSK9 Inhibitor
AstraZeneca Touts Early-Stage Results for Oral PCSK9 Inhibitor 5/29/2024
New therapy proven effective against rejection in kidney transplantation
Antibody-mediated rejection (AMR) is one of the most common causes of kidney transplant failure. To date, however, no treatment has proven effective in combating this complication in the long term. As part of an international and multidisciplinary clinical study led by Georg Böhmig and Katharina Mayer, Clinical Division of Nephrology and Dialysis, Department of Medicine III at MedUni Vienna and University Hospital Vienna, a new therapeutic principle in transplant medicine has been found to be both safe and highly effective.
J&J Inks $1.25B Deal to Buy Rights to Atopic Dermatitis Candidate from Numab
J&J Inks $1.25B Deal to Buy Rights to Atopic Dermatitis Candidate from Numab 5/28/2024
World Pharma News
- Novel drug application shows improved survival for patients with relapsed and refractory acute myeloid leukemia
- Study shows ancient viruses fuel modern-day cancers
- Darolutamide meets primary endpoint in Phase III ARANOTE trial
- Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist danuglipron
- New AI approach optimizes antibody drugs